Glaxo Wins U.S. Approval for HIV Treatment Developed by ViiV Joint Venture

GlaxoSmithKline Plc won U.S. regulatory approval for a daily pill against the deadly HIV infection that was developed by ViiV Healthcare Ltd., its joint venture with two other drugmakers.

http://www.bloomberg.com/news/2013-08-12/glaxo-wins-u-s-fda-approval-for-new-daily-hiv-therapy.html